Symbols

QURE

uniQure·NASDAQ

--(--)

QURE fundamentals

QURE Q4 2025 Earnings

uniQure (QURE) released its earnings on Mar 2, 2026: revenue was 5.57M (YoY +6.67%), beat estimates; EPS was -0.57 (YoY +61.74%), beat estimates.

Revenue / YoY

5.57M

+6.67%

EPS / YoY

-0.57

+61.74%

Report date

Mar 2, 2026

QURE Earnings Call Summary for Q4,2025

AMT-130 Data Strength: 75% disease progression slowing at 3 years vs. external control; 4-year follow-up planned to confirm durability.
FDA Regulatory Hurdle: Agency insists on Phase III sham-controlled trial despite natural history data precedent.
Ex-U.S. Regulatory Path: Pursuing MHRA/EMA engagement for expedited access via named patient programs.
Financial Resilience: $622M cash runway supports multiple late-stage programs; AMT-130 commercialization expenses up 24%.

Earnings

EPS

Revenue

Revenue & Expenses

QURE has released its 2025 Q4 earnings report, with revenue of 5.57M, reflecting a YoY change of 6.65%, and net profit of -37.09M, showing a YoY change of 49.38%. The Sankey diagram below clearly presents QURE's revenue sources and cost distribution.

Key Indicators

uniQure (QURE) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

uniQure (QURE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

uniQure (QURE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

uniQure (QURE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown